Sphera Funds Management LTD. lowered its position in Forward Pharma A/S (NASDAQ:FWP) by 11.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,023 shares of the biotechnology company’s stock after selling 13,477 shares during the period. Sphera Funds Management LTD. owned about 0.23% of Forward Pharma A/S worth $2,328,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of FWP. Perceptive Advisors LLC purchased a new position in shares of Forward Pharma A/S during the fourth quarter worth approximately $5,918,000. Sandia Holdings LLC purchased a new position in shares of Forward Pharma A/S during the fourth quarter valued at about $1,651,000. Eqis Capital Management Inc. purchased a new position in shares of Forward Pharma A/S during the first quarter valued at about $346,000. NJ State Employees Deferred Compensation Plan purchased a new position in shares of Forward Pharma A/S during the first quarter valued at about $323,000. Finally, Motley Fool Wealth Management LLC raised its position in shares of Forward Pharma A/S by 4.1% in the fourth quarter. Motley Fool Wealth Management LLC now owns 72,339 shares of the biotechnology company’s stock valued at $1,085,000 after buying an additional 2,844 shares during the period. Institutional investors own 22.24% of the company’s stock.

Institutional Ownership by Quarter for Forward Pharma A/S (NASDAQ:FWP)

Forward Pharma A/S (NASDAQ FWP) traded up 8.18% on Friday, hitting $21.96. The company had a trading volume of 70,493 shares. The company’s market capitalization is $1.04 billion. The stock’s 50-day moving average price is $19.74 and its 200 day moving average price is $22.41. Forward Pharma A/S has a one year low of $14.89 and a one year high of $33.00.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/06/16/sphera-funds-management-ltd-has-2-328-million-stake-in-forward-pharma-as-fwp-updated-updated.html.

Several equities analysts have weighed in on FWP shares. Zacks Investment Research raised Forward Pharma A/S from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research note on Wednesday, April 5th. Leerink Swann set a $28.00 price target on Forward Pharma A/S and gave the stock a “buy” rating in a research report on Monday, April 3rd. Jefferies Group LLC set a $22.00 price target on Forward Pharma A/S and gave the stock a “hold” rating in a research report on Tuesday, April 18th. Finally, JMP Securities downgraded Forward Pharma A/S from an “outperform” rating to a “market perform” rating in a report on Monday, April 3rd.

Forward Pharma A/S Company Profile

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Receive News & Stock Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related stocks with our FREE daily email newsletter.